SCHEMBL410781

SCHEMBL410781

CC1(C)CCCC(C)(C)N1OC(COC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
ADRB2 P07550 2/20 0.43
ADRB1 P08588 2/20 0.43
ADRB3 P13945 2/20 0.43
LMNA P02545 2/20 0.38
CHRNB2 P17787 1/20 0.38
CHRNA5 P30532 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
MAPK1 P28482 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
TSHR P16473 3/20 0.38
KMT2A Q03164 3/20 0.38
SLC6A2 P23975 2/20 0.37
SLC6A3 Q01959 2/20 0.37
SLC6A4 P31645 1/20 0.37
TDP1 Q9NUW8 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25501673 0.94 ALDH1A1 (0.38) ALDH1A1ADRB2ADRB1ADRB3LMNA
SCHEMBL12794193 0.90 ALDH1A1 (0.39) ALDH1A1ADRB2ADRB1ADRB3LMNA
SCHEMBL4886714 0.88 PABPC1 (0.41) ALDH1A1LMNATSHRKMT2ACHRM2
SCHEMBL5074915 0.85 CYP1A2 (0.48) ALDH1A1LMNAMAPK1CYP1A2CYP2C9
SCHEMBL17770893 0.84 L3MBTL1 (0.37) ALDH1A1ADRB2ADRB1ADRB3CHRNB2
SCHEMBL13041004 0.84 L3MBTL1 (0.37) ALDH1A1ADRB2ADRB1ADRB3CHRNB2
SCHEMBL13846311 0.84 LMNA (0.34) ALDH1A1LMNACYP1A2TSHRKMT2A
SCHEMBL12274081 0.84 TSHR (0.47) ALDH1A1ADRB2ADRB1ADRB3LMNA
SCHEMBL1005104 0.83 PABPC1 (0.39) ALDH1A1LMNAMAPK1CYP1A2CYP2C9
SCHEMBL29786589 0.83 THRB (0.36) ALDH1A1LMNATSHRKMT2ACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119677808-A Air-curable ethylene/alpha-olefin interpolymer compositions 陶氏环球技术有限责任公司 2025-03-21 CN disclosed
US-11814336-B2 Oligomeric alkoxy amines ARKEMA FRANCE (FR) 2023-11-14 US disclosed
US-11814336-B2 Oligomeric alkoxy amines ARKEMA FRANCE (FR) 2023-11-14 US disclosed
US-11733647-B2 Light-activated controlled radical polymerization META PLATFORMS TECHNOLOGIES, LLC (US) 2023-08-22 US disclosed
US-11733647-B2 Light-activated controlled radical polymerization META PLATFORMS TECHNOLOGIES, LLC (US) 2023-08-22 US disclosed
WO-2023119803-A1 RESIN COMPOSITION, PREPREG, RESIN-COATED FILM, RESIN-COATED METAL FOIL, METAL-CLAD LAMINATE, AND WIRING BOARD パナソニックIPマネジメント株式会社 2023-06-29 WO disclosed
US-11634528-B2 Latent imaging for volume Bragg gratings META PLATFORMS TECHNOLOGIES, LLC (US) 2023-04-25 US disclosed
WO-2022059625-A1 RESIN COMPOSITION, PREPREG USING SAME, FILM PROVIDED WITH RESIN, METAL FOIL PROVIDED WITH RESIN, METAL-CLAD LAMINATE, AND WIRING BOARD パナソニックIPマネジメント株式会社 2022-03-24 WO disclosed
US-20210139415-A1 OLIGOMERIC ALKOXYAMINES ARKEMA FRANCE (FR) 2021-05-13 US disclosed
US-20200356049-A1 LIGHT-ACTIVATED CONTROLLED RADICAL POLYMERIZATION META PLATFORMS TECHNOLOGIES, LLC 2020-11-12 US disclosed
WO-2010012712-A1 PROCESS TO MAKE A DIBLOCK COPOLYMER HAVING A MONOVINYLAROMATIC POLYMER BLOCK TOTAL PETROCHEMICALS FRANCE (FR) 2010-02-04 WO disclosed
US-7276565-B2 Continuous miniemulsion polymerization process XEROX CORPORATION (US) 2007-10-02 US disclosed
US-20070106040-A1 Polymers containing quaternized nitrogen REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 2007-05-10 US disclosed
EP-1754762-A1 ADHESIVE COMPOSITION, CIRCUIT CONNECTING MATERIAL, CONNECTING STRUCTURE FOR CIRCUIT MEMBER, AND SEMICONDUCTOR DEVICE Hitachi Chemical Co., Ltd. (JP) 2007-02-21 EP disclosed
US-20040260026-A1 Continuous miniemulsion polymerization process XEROX CORPORATION 2004-12-23 US disclosed
US-6767974-B1 HEATING AND ADDITION CO-POLYMERIZATION IN MIXTURE WITH FREE RADICAL CATALYSTS; SHEARING XEROX CORPORATION 2004-07-27 US disclosed
WO-2004050848-A2 METHODS FOR ANTIGEN MASKING OF RED BLOOD CELLS RESULTING IN REDUCED HEMOLYSIS CERUS CORPORATION (US) 2004-06-17 WO disclosed
EP-1192197-B1 METHOD FOR PRODUCING GRAFT COPOLYMERS, CONTAINING AN ELASTIC GRAFT COPOLYMER BACKBONE BASF AG (DE) 2002-12-04 EP disclosed
EP-1192197-A1 METHOD FOR PRODUCING GRAFT COPOLYMERS, CONTAINING AN ELASTIC GRAFT COPOLYMER BACKBONE BASF AKTIENGESELLSCHAFT (DE) 2002-04-03 EP disclosed
WO-2000077060-A1 METHOD FOR PRODUCING GRAFT COPOLYMERS, CONTAINING AN ELASTIC GRAFT COPOLYMER BACKBONE BASF AKTIENGESELLSCHAFT (DE) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139415-A1 OLIGOMERIC ALKOXYAMINES ALKBH3, ALK, ALKBH2 ALDH1A1 1307/4885ADRB2 217/4885ADRB1 426/4885
US-11814336-B2 Oligomeric alkoxy amines ALKBH3, ALK, PNMT ALDH1A1 1187/4885ADRB2 56/4885ADRB1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.